Tohoku University. Research Profiles

LANGUAGE
  • Top
  • Life Sciences
  • Biomarker Development and Preemptive Therapy of Alzheimer's Disease

Biomarker Development and Preemptive Therapy of Alzheimer's Disease

update:2019-02-21
  • JAPANESE
  • INQUIRY
  • seed-12-1-en.jpg
  • seed-12-2-en.jpg
NEXT
PREV
Features
Over the past 20 years, our understanding of molecular pathology of dementia and AD has dramatically deepened, and new biomarkers including amyloid PET and cerebrospinal fluid (CSF) amyloid42/tau as well as therapeutic strategies have been developed. However, clinical trials of disease-modifying drugs in mild to moderate AD were unsuccessful or were halted due to serious adverse drug effects.

Targeted Application(s)/Industry
These results strongly suggest that disease-modifying therapies should be started much earlier before a widespread neuron death will occur. We hope that early detection and prevention with preemptive therapy may lead to a success of fighting AD.

Researchers

Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer

ARAI, Hiroyuki , Professor
MD, PhD

Keywords

List